FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
HUMANINPEPPUDEX

HUMANIN · SUBTOPIC · MECHANISM

HUMANIN Mechanism

For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.

MECHANISM OF ACTION

Twenty-four-amino-acid peptide encoded in the mitochondrial 16S-rRNA (cousin to MOTS-c). Anti-apoptotic via BAX inhibition and neuroprotective in Alzheimer's-disease cell-line models. Discovered by Cohen group 2001 from cDNA library of dying neurons.

PHARMACOKINETIC HALF-LIFE

Reported half-life for HUMANIN: Short (minutes) plasma · longer in CNS. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.

PRIMARY SEQUENCE

HUMANIN is a defined sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (native 24-residue). Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.

MECHANISM CATEGORIES

HUMANIN is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.

Mitochondrial function encompasses oxidative phosphorylation, biogenesis (driven by PGC-1α), and quality-control processes (mitophagy). The mitochondrial-derived peptide MOTS-c regulates AMPK signaling and metabolic homeostasis. NAD+ supports the electron-transport chain and mitochondrial sirtuins (SIRT3, SIRT4, SIRT5).

Neurotrophic signaling encompasses BDNF, NGF, and the broader neurotrophin family, acting through Trk receptor tyrosine kinases. BDNF / TrkB signaling drives synaptic plasticity, neuronal survival, and learning. Semax is the most-studied research neurotrophic peptide.

MECHANISTIC OUTCOMES IN LITERATURE

The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.

Neuroprotection in Alzheimer cell modelsGRADE B

Hashimoto 2001 demonstrated humanin protects neurons against amyloid-beta toxicity in vitro and in rodent models.

Insulin sensitivity (rodent)GRADE B

Muzumdar 2009 demonstrated humanin improves insulin action in obese rats.

Longevity correlation (human)GRADE C

Circulating humanin levels correlate with longevity in human population studies (Lee et al., 2015).

MECHANISM Q+A

Why is humanin called a longevity peptide?

Circulating humanin levels decline with age. Centenarians and their offspring show elevated humanin levels relative to age-matched controls in some cohorts. The IGF-1/humanin axis (Lee et al., 2014, Aging Cell) connects mitochondrial-derived peptide signaling with growth-axis aging biology.

Is there a humanin variant called HNG?

HNG (S14G-humanin) is a synthetic analog with a serine-to-glycine substitution at position 14 that increases potency ~1000-fold in some cell models. It is the variant most commonly used in mechanism studies.

CITED LITERATURE

  • Hashimoto Y, Niikura T, Tajima H, et al.. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A 2001. PMID 11371646. link
  • Muzumdar RH, Huffman DM, Atzmon G, et al.. Humanin: a novel central regulator of peripheral insulin action. PLoS One 2009. PMID 19470690. link
  • Lee C, Wan J, Miyazaki B, Fang Y, Guevara-Aguirre J, Yen K, Longo VD, Bartke A, Cohen P. IGF-I regulates the age-dependent signaling peptide humanin. Aging Cell 2014. link

RELATED PAGES

HUMANIN OVERVIEWDOSING LITERATURE ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19

© 2026 Peppu Studio LLC · For Laboratory Research Use Only